What could change the investment decision?

Setup and review are real work, so the pilot counts them. The proposed approach starts with an owner-accepted operating map and one bounded workflow, using imports and reviewed configuration where they help. Measure customer onboarding hours, ongoing intervention, time to the first accepted outcome and Rōvn support separately.

If the first result requires excessive recurring coordination, simplify the scope or repair the repeated step before expanding. The buyer should see a net improvement after the full delivery burden, not a faster isolated task. Inspect the smaller-facility test.

The proposed value is completing work that crosses teams and systems: requirements, evidence, ownership, decisions and accepted handoffs. Existing systems may remain authoritative for their own records. The pilot must show why coordinating that journey through Rōvn is worth the additional purchase.

The comparison should include improving the facility’s process or extending an installed platform. If those alternatives deliver the same outcome more economically, a generic AI claim is not a reason to choose us. Read the alternative approaches.

Twelve healthcare organizations acknowledged non-binding letters between July 7 and September 21, 2026. Three more letters are out and not yet acknowledged. The packet supports documented interest; it does not establish current signed pilots, payment or deployment eligibility.

The next step is to confirm the actual buyer, current scope, permissions and commercial unit. Historical 90-day, site-priced proposals are not automatically changed by the later 180-day per-bed plan. Inspect the count and its meaning.

Qualification must identify budget authority, procurement, data/security reviewers and the people needed to run the workflow. A supportive contact can help establish the problem without being able to commit the organization.

If the blocker is an unresolved requirement, keep that dependency visible and complete eligible preparation. If urgency or willingness to pay is absent, change the proposed scope or qualification rather than report the prospect as a customer. Read the qualification method.

The first deployments will require implementation work. The business earns a recurring software interpretation through repeatable delivery: less setup for comparable scope, bounded support, useful ongoing operations and revenue that exceeds Rōvn’s own delivery costs.

Track implementation, support, checks, model use and recovery per deployment and accepted outcome. Founder effort cannot be treated as free. If every additional customer requires a bespoke operating team, the scope and economics need to change before scale is claimed. Examine delivery economics.

The current plan is a prepaid 180-day pilot at $30 per certified bed per month. Planned production list prices are $20 for Readiness and $60 for Operator, per certified bed per month. The production rate is the lesser of list and one third of finance-signed savings. Clinicians do not pay; the unit for organizations without certified beds remains to be set.

The pilot does not automatically convert. Production scope and measurement terms require a separate agreement. Read the arithmetic, costs and qualifications.

Released staff capacity can be useful without reducing spending. Report those hours separately, including review and rework. Cash savings require an evidenced spending change; additional contribution requires its own attribution and variable-cost treatment.

The facility’s finance lead accepts the eligible savings under the agreement. A notional wage value must not be counted as cash while the same staff remain employed at the same cost. If the measured value does not support the commercial decision, revise the package or end the pilot as planned. Inspect the measurement ledger.

A generated draft, dispatched request and acknowledgement are different states. The intended completion record requires a source-confirmed, facility-accepted destination and the relevant evidence and human decisions. A first-start claim needs evidence of first worked shift, not only a scheduled date.

When a write may have succeeded but the response was lost, reconcile before retrying. Preserve the exception and recovery record. The acceptance standard is the customer outcome, not the number of actions the agent attempted. Follow the handoff model.

The first product must earn its value inside one facility. Cross-facility reuse is a separate test: record the eligible item offered, consent, source freshness, the receiving requirement, its acceptance or refusal and the effort saved.

A refusal can reveal a source, identity, freshness or policy gap. It is useful evidence for improving the record; it must not be counted as a successful reuse. The second facility keeps its own decision rights and orders its own background report. Read what must accumulate.

The proposed purchase is useful workforce operation within the facility: less avoidable preparation, an organized current workforce and clearer handoffs. Portability can create reciprocal value when eligible incoming evidence is accepted. That value must be measured rather than assumed.

The clinician retains control of sharing and eligible export. Retention should come from ongoing product usefulness, not trapping a career record. A buyer who values only restrictive ownership would be asking for a different product. Read the retention thesis.

The investment thesis does not rest on exclusive access to models or uncopyable workflow controls. Capable competitors can build strong products. Our proposed lead must appear in useful operating history, accepted evidence, continuing professional relationships and repeatable delivery.

The internal Vision Lab challenged technical-moat claims and treated compounding acceptance as the question to prove. A stored file count is not that proof; the next authorized workflow has to become more useful. Examine the defensibility argument.

No. One facility’s private data, policies and pipeline cannot inform another facility, including through weights or aggregates. The design separates facility-local operating intelligence from clinician-consented portable evidence and permitted non-facility information.

Any broader offering needs a specific useful decision, authorized data rights, evaluation and a buyer. Potential facilities, planners or other healthcare buyers are an expansion hypothesis, not a current data business. Professional data is not for sale. Explore the company model.

Workforce operations is the entry. The intended company combines a healthcare career network, an agent-operated facility system and permissioned operating intelligence. Career identity and opportunities belong in the initial experience; broader community participation develops from useful work.

The facility direction is a connected practice across departments. Each additional package needs demand, a responsible owner, permitted sources and an accepted outcome. A broad operating map can guide the architecture without activating every department at once. Read the complete vision package.

Named authorized people retain consequential hiring, offer, rejection, credentialing, privileging, assignment, scheduling and start decisions where applicable. Agents prepare and perform permitted administrative work; a model answer creates neither authority nor source truth.

The clinician and facility are separate principals. Each grant has its own scope, and a failure or revocation can block dependent work. The relevant control must be demonstrated for the actual release. Review the authority model.

A workflow that cannot be authorized, persistent customer effort above the agreed budget, repeated recovery failures, insufficient measured benefit or poor paid continuation should change scope or delivery. Those results should be tied to a cohort and observation period so the decision has a basis.

The broader ambition remains a direction, while the next release concentrates on what can be delivered dependably. An unresolved future department need not delay an otherwise eligible workforce path. Read the response to missed assumptions.

The $1.5M round is intended to turn acknowledged interest and product development into signed pilots, measured starts and evidence of repeatability. The financing plan is a post-money SAFE with a target cap of $7.5M–$10M set with the lead; definitive documents govern.

The core evidence is commercial commitment, an accepted operating outcome, finance-reviewed value and a sustainable cost to repeat. The network and whole-practice thesis become stronger as their own evidence arrives. Connect capital to the proof plan.